What is polypharmacy in the context of geriatric care?

Polypharmacy in geriatrics refers to the concurrent use of multiple medications, often defined as five or more. More critically, it encompasses the use of potentially inappropriate medications (PIMs), medications without a clear indication, or when the risks outweigh the benefits in an older adult, regardless of the number of drugs.

Why is deprescribing crucial for older adults?

Deprescribing is crucial to reduce the risks associated with polypharmacy, such as adverse drug events (ADEs), drug-drug interactions, falls, cognitive impairment, and decreased quality of life. It aims to optimize medication regimens by discontinuing medications that are no longer beneficial or are causing harm.

What are some common tools or criteria used for identifying potentially inappropriate medications (PIMs)?

Key tools include the American Geriatrics Society (AGS) Beers Criteria, STOPP (Screening Tool of Older Persons' Prescriptions) Criteria, and START (Screening Tool to Alert doctors to Right Treatment) Criteria. These provide explicit guidance for identifying PIMs and prescribing omissions in older adults.

What medication classes are frequently targeted for deprescribing?

Common targets for deprescribing include benzodiazepines, Z-drugs (e.g., zolpidem), proton pump inhibitors (PPIs) for long-term use, antipsychotics used off-label, sulfonylureas (due to hypoglycemia risk), and non-steroidal anti-inflammatory drugs (NSAIDs) in patients with high cardiovascular, renal, or GI risk.

What are the primary barriers to successful deprescribing?

Barriers include patient reluctance, prescriber discomfort with discontinuing medications, fear of withdrawal symptoms or disease relapse, lack of time, fragmented care, and the challenge of managing multiple prescribers. Effective communication and shared decision-making are vital to overcome these barriers.

How does deprescribing relate to a patient's goals of care?

Deprescribing should always be patient-centered and aligned with the individual's goals of care. For example, in a patient with limited life expectancy, the focus might shift from preventive medications to those that improve comfort and quality of life, even if discontinuing some medications means accepting a higher risk of future events.

What is the role of the geriatric pharmacist in deprescribing?

The geriatric pharmacist plays a pivotal role by systematically reviewing medication regimens, identifying PIMs, assessing drug-related problems, facilitating shared decision-making with patients and caregivers, and collaborating with the healthcare team to develop and monitor deprescribing plans.

Polypharmacy & Deprescribing Strategies for the BCGP Board Certified Geriatric Pharmacist Exam

Introduction: Navigating Polypharmacy and Mastering Deprescribing for the BCGP Exam

As an aspiring Board Certified Geriatric Pharmacist (BCGP), understanding polypharmacy and mastering deprescribing strategies is not just a theoretical exercise—it's a critical skill that directly impacts patient outcomes in older adults. This topic is consistently a high-yield area on the Complete BCGP Board Certified Geriatric Pharmacist Guide, reflecting its prevalence and complexity in geriatric practice. With the increasing aging population, pharmacists are at the forefront of optimizing medication regimens to enhance safety, improve quality of life, and reduce healthcare costs.

Polypharmacy, commonly defined as the concurrent use of five or more medications, is widespread among older adults. However, the true concern lies not just in the number of medications, but in the appropriateness of each drug for the individual patient. Inappropriate polypharmacy can lead to a cascade of adverse events, making deprescribing a vital intervention. Deprescribing is the systematic process of identifying and discontinuing medications where the potential harms outweigh the potential benefits, in consultation with the patient and their caregivers. For the BCGP exam, you'll need to demonstrate a deep understanding of identifying at-risk patients, applying evidence-based tools, and implementing patient-centered deprescribing plans.

Key Concepts: Understanding the Landscape of Polypharmacy and Deprescribing

To excel on the BCGP exam, a solid grasp of the following concepts is essential:

Defining Polypharmacy: More Than Just a Number

Numerical Polypharmacy: Often cited as ≥5 medications. While a useful screening tool, it doesn't always equate to inappropriate care.
Inappropriate Polypharmacy: This is the true clinical challenge. It refers to the use of medications that are not clinically indicated, are duplicative, are at an inappropriate dose, or whose risks outweigh their benefits, especially in the context of an older adult's comorbidities, functional status, and goals of care.

Consequences of Inappropriate Polypharmacy in Older Adults

The impact of inappropriate polypharmacy extends far beyond drug interactions. It significantly compromises patient safety and quality of life:

Adverse Drug Events (ADEs): Increased risk of side effects, often subtle and misinterpreted as new medical conditions.
Drug-Drug and Drug-Disease Interactions: Higher likelihood of harmful interactions due to multiple medications and altered pharmacokinetics/pharmacodynamics.
Increased Fall Risk: Medications like sedatives, hypnotics, anticholinergics, and antihypertensives can contribute to dizziness, orthostatic hypotension, and impaired balance.
Cognitive Impairment/Delirium: Certain medications (e.g., anticholinergics, benzodiazepines) can worsen or induce cognitive decline.
Functional Decline: Sedation, weakness, and dizziness can impair mobility and independence.
Reduced Medication Adherence: Complex regimens can be overwhelming, leading to missed doses or incorrect administration.
Increased Healthcare Utilization and Costs: More doctor visits, emergency department visits, hospitalizations, and medication expenses.

Principles of Deprescribing: A Patient-Centered Approach

Deprescribing is not merely about stopping drugs; it's a thoughtful, systematic process:

Assess Overall Medication Burden: Review all prescribed, over-the-counter (OTC), and herbal medications.
Identify Patient's Goals of Care: What matters most to the patient? Is it comfort, longevity, independence, or symptom relief? This guides decisions.
Review for Potentially Inappropriate Medications (PIMs): Use evidence-based criteria and clinical judgment.
Prioritize Medications for Deprescribing: Start with those with the highest risk, least benefit, or those conflicting with goals of care.
Develop a Deprescribing Plan: This involves shared decision-making with the patient/caregiver, determining the tapering schedule (if needed), and monitoring for withdrawal or disease recurrence.
Monitor and Evaluate: Follow up to assess benefits, harms, and patient acceptance.

Tools and Criteria for Identifying PIMs and Optimizing Prescribing

The BCGP exam will test your familiarity and application of these critical tools:

American Geriatrics Society (AGS) Beers Criteria (Updated 2023): The cornerstone for identifying PIMs in older adults. You must know its categories (e.g., PIMs to avoid, PIMs to avoid with certain diseases/syndromes, PIMs to use with caution, drug-drug interactions, dose adjustments based on renal function). Be prepared to apply these criteria to patient cases.
STOPP (Screening Tool of Older Persons' Prescriptions) Criteria: Explicit criteria for identifying potentially inappropriate prescribing. It's often used in conjunction with START.
START (Screening Tool to Alert doctors to Right Treatment) Criteria: Explicit criteria for identifying potential prescribing omissions (i.e., when a beneficial medication is indicated but not prescribed).
Medication Appropriateness Index (MAI): A comprehensive tool assessing the appropriateness of each medication based on ten criteria (e.g., indication, effectiveness, dose, drug-drug interactions).
Anticholinergic Burden Scales: Tools like the Anticholinergic Cognitive Burden (ACB) Scale quantify the cumulative anticholinergic effect of medications, which can significantly impact cognitive function in older adults.

Common Medication Classes Targeted for Deprescribing

Be prepared to identify these frequently problematic drug classes:

Benzodiazepines and Z-drugs (e.g., zolpidem): High risk of falls, sedation, cognitive impairment, and dependence.
Proton Pump Inhibitors (PPIs): Long-term use associated with increased risk of C. difficile infection, fractures, and vitamin B12 deficiency. Often overused for conditions that could be managed differently.
Antipsychotics: Increased mortality risk in dementia-related psychosis, significant side effects (e.g., extrapyramidal symptoms, sedation, metabolic effects).
Sulfonylureas (e.g., glyburide): High risk of hypoglycemia in older adults, especially those with impaired renal function or poor nutritional intake.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Increased risk of gastrointestinal bleeding, renal dysfunction, and cardiovascular events.
Antihypertensives: Can contribute to orthostatic hypotension and falls, especially in frail patients or those with aggressive blood pressure targets.
Cholinesterase Inhibitors and Memantine: Re-evaluate benefit in advanced dementia or when side effects outweigh modest benefits.

How It Appears on the Exam: BCGP Question Styles

The BCGP exam will assess your ability to apply these concepts to real-world clinical scenarios. Expect questions that:

Present Clinical Vignettes: You'll be given a patient case, including demographics, comorbidities, current medication list, and lab values. You'll then be asked to identify PIMs, propose a deprescribing plan, or identify potential drug-related problems.
Direct Application of Criteria: Questions might specifically ask you to identify a medication that meets Beers Criteria for avoidance in a given patient profile or to apply STOPP/START criteria.
Prioritization of Deprescribing: Given a list of medications, you may be asked to determine which drug should be considered for deprescribing first, based on risk, benefit, and patient goals.
Shared Decision-Making: Scenarios might test your understanding of how to communicate deprescribing recommendations to patients and caregivers, addressing their concerns and preferences.
Monitoring for Withdrawal/Rebound: Questions may involve identifying potential withdrawal symptoms or disease recurrence after deprescribing and how to manage them.
Pharmacokinetic/Pharmacodynamic Changes: Linking age-related physiological changes to the increased risk of certain medications and the rationale for deprescribing.

Practicing with BCGP Board Certified Geriatric Pharmacist practice questions that include detailed clinical cases is invaluable for preparing for these types of questions.

Study Tips: Efficient Approaches for Mastering This Topic

To effectively prepare for the polypharmacy and deprescribing section of the BCGP exam:

Thoroughly Review the Latest Beers Criteria: Understand each category and be able to recall specific examples. Don't just memorize; understand the rationale behind each recommendation. For the April 2026 exam, the 2023 update of the Beers Criteria is highly relevant.
Familiarize Yourself with STOPP/START Criteria: While Beers focuses on what to avoid, STOPP/START provides a more comprehensive framework for both inappropriate prescribing and prescribing omissions across physiological systems.
Practice Case Studies: Work through as many patient cases as possible. For each case, systematically review the medication list, identify potential drug-related problems, and formulate a deprescribing plan. Consider the patient's age, comorbidities, renal/hepatic function, and goals of care.
Understand the "Why": Don't just know *what* to deprescribe, but *why*. Understand the specific risks associated with each PIM in older adults.
Focus on Communication Strategies: Deprescribing isn't just clinical; it's also about communication. Think about how you would explain the rationale for deprescribing to a patient or their family.
Utilize Practice Questions: Engage with free practice questions and comprehensive question banks. Pay attention to the rationales for correct and incorrect answers to deepen your understanding.
Create a "High-Risk Meds" List: Compile a personal list of medications frequently associated with ADEs in older adults and their common alternatives or management strategies.

Common Mistakes: What to Watch Out For

Avoid these pitfalls that can lead to incorrect answers on the exam and suboptimal patient care:

Ignoring Patient Goals of Care: Deprescribing decisions must always be aligned with what the patient values most. A common mistake is to apply a blanket deprescribing rule without considering the individual's preferences or functional status.
Abrupt Discontinuation: Many medications (e.g., benzodiazepines, beta-blockers, antidepressants) require gradual tapering to avoid severe withdrawal symptoms or rebound effects. Always consider a tapering schedule.
Failing to Monitor: Deprescribing requires careful monitoring for both withdrawal symptoms and recurrence or worsening of the condition the medication was treating.
Overlooking Drug-Drug or Drug-Disease Interactions During Deprescribing: Removing one medication might alter the pharmacokinetics or pharmacodynamics of remaining drugs, potentially creating new problems.
Underestimating Anticholinergic Burden: Many commonly used drugs (e.g., antihistamines, tricyclic antidepressants, some muscle relaxants) have anticholinergic properties. Failing to recognize the cumulative effect can lead to cognitive impairment or delirium.
Focusing Solely on the Number of Medications: While a high number is a red flag, the appropriateness of each medication is paramount. A patient on 10 appropriate medications may be safer than one on 4 inappropriate ones.
Not Considering the "Cascade Prescribing" Effect: This occurs when a new medication is prescribed to treat a side effect of another medication, rather than addressing the root cause. Recognize and break this cycle.

Quick Review / Summary

Polypharmacy and deprescribing are central to the practice of geriatric pharmacy and a critical component of the BCGP exam. Remember that inappropriate polypharmacy significantly increases the risk of adverse drug events, falls, cognitive decline, and reduced quality of life in older adults. Your role as a BCGP-certified pharmacist involves systematically reviewing medication regimens, utilizing evidence-based tools like the Beers Criteria and STOPP/START, and engaging in patient-centered shared decision-making to safely and effectively deprescribe unnecessary or harmful medications.

By mastering these concepts, understanding common exam scenarios, and diligently practicing with targeted questions, you will not only be well-prepared for the BCGP exam but also equipped to make a profound positive impact on the health and well-being of your geriatric patients.